Exactech 2014 Revenue Up 5% to $248.4 Million, Net Income Up 7% to $16.5 Million, EPS $1.18; Q4 Revenue Up 3% to $63.3M, Net Income Up 11% to $5.1M, EPS $0.36
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder and spine, announced today that revenue for 2014 increased 5% to $248.4 million from $237.1 million in 2013. Diluted earnings per share for the year was $1.18 based on net income of $16.5 million, representing a 7% increase compared to net income of $15.4 million or $1.12 diluted earnings per share during 2013.
2014 Full Year Highlights and Segment Performance
o Revenue for the year increased 5% to $248.4 million
o Extremity implant revenue increased 21% to $79.0 million
o Knee implant revenue decreased 2% to $78.7 million
o Hip implant revenue increased 6% to $43.5 million
o Biologic & spine revenues decreased 7% to $23.8 million
o Other revenues decreased 5% to $23.4 million
2014 Fourth Quarter Highlights and Segment Performance
For the fourth quarter of 2014 revenue was $63.3 million, an increase of 3% over $61.6 million for the comparable period last year. Net income for the fourth quarter of 2014 increased 11% to $5.1 million, or $0.36 per diluted share, compared to $4.6 million, or $0.33 per diluted share, for the fourth quarter of 2013. Fourth quarter total and segment revenues were as follows:
o Total revenue for the quarter increased 3% to $63.3 million
o Extremity implant revenue increased 18% to $21.7 million
o Knee implant revenue decreased 7% to $18.9 million
o Hip implant revenue increased 12% to $11.3 million
o Biologic & spine revenues decreased 8% to $6.1 million
o Other revenues decreased 13% to $5.2 million
Exactech CEO and President David Petty said, “Total sales were up 5% to $248.4 million in 2014. Continuing double-digit strength in our shoulder segment resulted in our extremities implant revenue emerging as our largest revenue segment in 2014 with an increase of 21% to $79.0 million.
“The major success of our shoulder business was directly attributable to excellent results that our surgeon customers continue to achieve with our Equinoxe(R) shoulder system. With a strong pipeline of new products and a well-established competency in the segment, we believe this will continue to be a robust business segment in 2015. Our hip business received a strong boost during the year with introduction of the Alteon(R) brand, which features a Tapered Wedge Femoral Stem and Neck Preserving Femoral Stem. These innovations have also produced very positive feedback from surgeons, providing us with excellent momentum going into the new year.
“Currency issues had a particularly specific impact on our knee revenues, which represent the largest volume product that we sell outside of the U.S. Knee unit sales increased on a worldwide basis during the year although revenues slipped, as pricing pressure was a factor. Based upon new product launches, sales force engagement, sales organization development and the product development pipeline, we see a number of positives in our knee business that we expect to be beneficial in the second half of 2015.
“U.S. sales for the year were up 4% to $165.6 million compared with $159.6 million in 2013. International sales increased 7% to $82.8 million. U.S. sales represented 67% of total sales and international sales were 33% of the total. For the fourth quarter of 2014 U.S. sales remained constant at $41.7 million as compared to the fourth quarter of 2013. International sales increased 9% to $21.6 million for the fourth quarter of 2014, which represented 34% of total sales,” Petty said.
Chief Financial Officer Jody Phillips said, “Full year gross margins increased to 70% compared with 69% for 2013 due to manufacturing cost reductions that offset some pricing pressure. Total operating expenses for the year increased 6% to $147.9 million and as a percentage of sales increased to 59.5% from 59.1% resulting in an operating profit increase of 10% to $26.3 million. Currency losses and income taxes significantly impacted our net income in the fourth quarter. The currency loss of $677,000 was partially offset by reinstatement of the Research and Development tax credit during the quarter.”
Looking forward, Exactech released its initial 2015 revenue guidance of $252-$260 million and diluted EPS target of $1.20-$1.28. For the first quarter of 2015, the company anticipates USGAAP revenues of $62-$65 million and diluted EPS of $0.30-$0.32. The foregoing statements regarding targets for the quarter and full year are forward-looking and actual results may differ materially. These are the company’s targets, not predictions of actual performance.
The financial statements are below.
The company will hold a conference call with CEO David Petty and key members of the management team on Wednesday, February 18th at 10:00 a.m. Eastern Time. The call will cover Exactech’s fourth quarter and year end 2014 results. Petty will open the conference call and a question-and-answer session will follow.
To participate in the call, dial 1-888-504-7963 any time after 9:50 a.m. Eastern on February 18th. International and local callers should dial 1-719-457-2627. A live webcast of the call will be available at http://www.hawkassociates.com/profile/exac.cfm or http://public.viavid.com/index.php?id=112991. This call will be archived for approximately 90 days.
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.
EXACTECH, INC. AND SUBSIDIARIES
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|December 31,||December 31,|
|Cash and cash equivalents||$||10,051||$||6,011|
|Accounts receivable, net of allowances of $946 and $993||50,731||59,109|
|Prepaid expenses and other assets, net||2,436||2,865|
|Income taxes receivable||1,492||1,331|
|Inventories – current||72,827||71,590|
|Deferred tax assets – current||1,620||1,653|
|Total current assets||139,157||142,559|
|PROPERTY AND EQUIPMENT:|
|Machinery and equipment||35,434||35,439|
|Furniture and fixtures||4,556||4,200|
|Projects in process||1,166||852|
|Total property and equipment||165,021||157,795|
|Net property and equipment||80,106||81,668|
|Deferred financing and deposits, net||676||870|
|Product licenses and designs, net||8,641||9,457|
|Patents and trademarks, net||1,701||2,005|
|Customer relationships, net||203||669|
|Total other assets||41,777||37,615|
|LIABILITIES AND SHAREHOLDERS’ EQUITY|
|Income taxes payable||146||39|
|Accrued expenses and other liabilities||9,194||10,974|
|Other current liabilities||250||250|
|Current portion of long-term debt||3,000||3,000|
|Total current liabilities||26,205||30,517|
|Deferred tax liabilities||2,794||4,200|
|Line of credit||–||10,732|
|Long-term debt, net of current portion||20,250||23,250|
|Other long-term liabilities||420||719|
|Total long-term liabilities||23,464||38,901|
|Additional paid-in capital||76,126||69,175|
|Accumulated other comprehensive loss||(8,397||)||(3,902||)|
|Total shareholders’ equity||211,371||192,424|
|TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY||$||261,040||$||261,842|
|EXACTECH, INC. AND SUBSIDIARIES|
|CONDENSED CONSOLIDATED STATEMENTS OF INCOME|
|(in thousands, except per share amounts)|
|Three Month Period||Twelve Month Periods|
|Ended December 31,||Ended December 31,|
|COST OF GOODS SOLD||19,116||19,228||74,244||73,019|
|Sales and marketing||21,894||21,718||89,796||84,999|
|General and administrative||5,860||5,348||22,692||21,149|
|Research and development||4,856||4,279||18,377||17,802|
|Depreciation and amortization||4,255||4,198||16,990||16,190|
|Total operating expenses||36,865||35,543||147,855||140,140|
|INCOME FROM OPERATIONS||7,331||6,807||26,274||23,929|
|OTHER INCOME (EXPENSE):|
|Foreign currency loss||(677||)||(132||)||(1,129||)||(444||)|
|Total other income (expense)||(900||)||(431||)||(2,146||)||(1,521||)|
|INCOME BEFORE INCOME TAXES||6,431||6,376||24,128||22,408|
|PROVISION FOR INCOME TAXES||1,312||1,781||7,640||7,036|
|BASIC EARNINGS PER SHARE||$||0.37||$||0.34||$||1.20||$||1.14|
|DILUTED EARNINGS PER SHARE||$||0.36||$||0.33||$||1.18||$||1.12|
|SHARES – BASIC||13,837||13,546||13,732||13,462|
|SHARES – DILUTED||14,083||13,844||14,016||13,683|
Sorry. No data so far.